Pay in 4 interest-free payments of $7.14 Learn more
Ships within 48 hours · Estimated delivery Aug 29 - Sep 3
Clinical Evidence Summary Study Type: Retrospective analysis (not a randomized controlled trial) Participants: 1,131 program completers with BMI 30 Duration: 52-68 weeks Primary Outcome: 19.5% average body weight reduction at 52 weeks Medication: 95.4% compounded semaglutide, 4.6% branded semaglutide Control Group: None Funding/Authors: Ivm Health-affiliated authors (conflict of interest disclosed) Publication: Obesity Pillars , 2025 (PubMed indexed, peer-reviewed) Key Limitation: Self-selected completers
Conclusion Taking BPC 157 can be a valuable addition to your wellness routine, offering support for tissue repair, inflammation reduction, and overall recovery
ArticlePubMedPMC 14
A modest but significant LBM loss (2%) also occurred
